Literature DB >> 21428295

Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors.

Maithé Corbani1, Miguel Trueba, Stoytcho Stoev, Brigitte Murat, Julie Mion, Véra Boulay, Gilles Guillon, Maurice Manning.   

Abstract

Among the four known vasopressin and oxytocin receptors, the specific localization of the V1b isoform is poorly described because of the lack of selective pharmacological tools. In an attempt to address this need, we decided to design, synthesize, and characterize fluorescent selective V1b analogues. Starting with the selective V1b agonist [deamino-Cys(1),Leu(4),Lys(8)]vasopressin (d[Leu(4),Lys(8)]VP) synthesized earlier, we added blue, green, or red fluorophores to the lysine residue at position 8 either directly or by the use of linkers of different lengths. Among the nine analogues synthesized, two exhibited very promising properties. These are d[Leu(4),Lys(Alexa 647)(8)]VP (3) and d[Leu(4),Lys(11-aminoundecanoyl-Alexa 647)(8)]VP (9). They remained full V1b agonists with nanomolar affinity and specifically decorated the plasma membrane of CHO cells stably transfected with the human V1b receptor. These new selective fluorescent peptides will allow the cellular localization of V1b or OT receptor isoforms in native tissues.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21428295      PMCID: PMC3104497          DOI: 10.1021/jm1016208

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  54 in total

Review 1.  Appearance and transient expression of vasopressin and oxytocin receptors in the rat brain.

Authors:  E Tribollet; M Goumaz; M Raggenbass; J J Dreifuss
Journal:  J Recept Res       Date:  1991

2.  Solid-phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocin.

Authors:  M Manning; M Kruszynski; K Bankowski; A Olma; B Lammek; L L Cheng; W A Klis; J Seto; J Haldar; W H Sawyer
Journal:  J Med Chem       Date:  1989-02       Impact factor: 7.446

3.  Synthesis and some of the pharmacological properties of (4-leucine)-8-lysine-vasopressin and (1-deamino,4-leucine)-8-lysine-vasopressin.

Authors:  D F Dyckes; M F Ferger; V Du Vigneaud; W Y Chan
Journal:  J Med Chem       Date:  1973-07       Impact factor: 7.446

4.  Synthesis of the alpha-hydroxy-analogues of S-benzylcysteine and cysteine.

Authors:  D B Hope; M Wälti
Journal:  J Chem Soc Perkin 1       Date:  1970

5.  Extrapituitary expression of the rat V1b vasopressin receptor gene.

Authors:  S J Lolait; A M O'Carroll; L C Mahan; C C Felder; D C Button; W S Young; E Mezey; M J Brownstein
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-18       Impact factor: 11.205

6.  Vasopressin antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis.

Authors:  S Jard; R C Gaillard; G Guillon; J Marie; P Schoenenberg; A F Muller; M Manning; W H Sawyer
Journal:  Mol Pharmacol       Date:  1986-08       Impact factor: 4.436

7.  Fluorescent peptide hormones: development of high affinity vasopressin analogues.

Authors:  G Guillon; D Barbeau; W Neugebauer; S Guay; L Bilodeau; M N Balestre; N Gallo-Payet; E Escher
Journal:  Peptides       Date:  1992 Jan-Feb       Impact factor: 3.750

8.  125I-labelled d(CH2)5[Tyr(Me)2,Thr4,Tyr-NH2(9)]OVT: a selective oxytocin receptor ligand.

Authors:  J Elands; C Barberis; S Jard; E Tribollet; J J Dreifuss; K Bankowski; M Manning; W H Sawyer
Journal:  Eur J Pharmacol       Date:  1988-03-01       Impact factor: 4.432

9.  [125I]-[d(CH2)5, Sar7]AVP: a selective radioligand for V1 vasopressin receptors.

Authors:  J M Kelly; J M Abrahams; P A Phillips; F A Mendelsohn; Z Grzonka; C I Johnston
Journal:  J Recept Res       Date:  1989

10.  [1-beta-Mercapto-beta,beta-cyclopentamethylenepropionic acid),2-(O-methyl)tyrosine ]argine-vasopressin and [1-beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)]argine-vasopressine, two highly potent antagonists of the vasopressor response to arginine-vasopressin.

Authors:  M Kruszynski; B Lammek; M Manning; J Seto; J Haldar; W H Sawyer
Journal:  J Med Chem       Date:  1980-04       Impact factor: 7.446

View more
  6 in total

1.  V1b and CRHR1 receptor heterodimerization mediates synergistic biological actions of vasopressin and CRH.

Authors:  Brigitte Murat; Dominic Devost; Miriam Andrés; Julie Mion; Véra Boulay; Maithé Corbani; Hans H Zingg; Gilles Guillon
Journal:  Mol Endocrinol       Date:  2012-02-02

2.  Palladium-Mediated Arylation of Lysine in Unprotected Peptides.

Authors:  Hong Geun Lee; Guillaume Lautrette; Bradley L Pentelute; Stephen L Buchwald
Journal:  Angew Chem Int Ed Engl       Date:  2017-02-16       Impact factor: 15.336

3.  Functional assay for T4 lysozyme-engineered G protein-coupled receptors with an ion channel reporter.

Authors:  Katarzyna Niescierowicz; Lydia Caro; Vadim Cherezov; Michel Vivaudou; Christophe J Moreau
Journal:  Structure       Date:  2013-11-21       Impact factor: 5.006

Review 4.  Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics.

Authors:  M Manning; A Misicka; A Olma; K Bankowski; S Stoev; B Chini; T Durroux; B Mouillac; M Corbani; G Guillon
Journal:  J Neuroendocrinol       Date:  2012-04       Impact factor: 3.627

5.  Vasopressin inhibits LTP in the CA2 mouse hippocampal area.

Authors:  Magda Chafai; Maithé Corbani; Gilles Guillon; Michel G Desarménien
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

Review 6.  Vasopressin and Its Analogues: From Natural Hormones to Multitasking Peptides.

Authors:  Mladena Glavaš; Agata Gitlin-Domagalska; Dawid Dębowski; Natalia Ptaszyńska; Anna Łęgowska; Krzysztof Rolka
Journal:  Int J Mol Sci       Date:  2022-03-12       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.